会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 6. 发明申请
    • AKT INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF
    • AKT抑制剂,药物组合物及其用途
    • WO2004022569A9
    • 2004-06-10
    • PCT/US0327607
    • 2003-09-03
    • UNIV GEORGETOWNUS GOV HEALTH & HUMAN SERVKOZIKOWSKI ALAN PDENNIS PHILLIPSUN HAIYINGBROGNARD JOHN
    • KOZIKOWSKI ALAN PDENNIS PHILLIPSUN HAIYINGBROGNARD JOHN
    • A61K31/683A61K31/66A61P9/00A61P11/00A61P11/08A61P15/00A61P17/00A61P19/02A61P25/00A61P29/00A61P31/04A61P31/12A61P31/14A61P33/00A61P35/00A61P35/02A61P43/00C07C43/196C07F9/02C07F9/117A61K31/185C07C59/13C07C59/68
    • C07C43/196C07C2601/14C07F9/117
    • Disclosed are inhibitors of the serine/threonine kinase Akt, pharmaceutical compositions comprising such inhibitors, and a method of preventing or treating a disease or condition in an animal by the use of such inhibitors. The Akt inhibitors have the formula (I) wherein X and Y are independently selected from the group consisting of O, CF2, CH2, and CHF; wherein A is independently selected from the group consisting of P(O)OH, CH2000H, and CH(COOH)2; R2 is selected from the group consisting of H, OH, isosteres of OH, C1-C25 alkyloxy, C6-Cl0 aryloxy, C3-C8 cycloalkyloxy, C3-C8 cycloalkyl C1-C6 alkoxy, C2-C22 alkenyloxy, C3-C8 cycloalkenyloxy, C7-C32 aralkyloxy, C7-C32 alkylaryloxy, C9-C32 aralkenyloxy, and C9-C32 alkenylaryloxy; R3-R6 are independently selected from the group consisting of H, OH, isosteres of OH; and Rl and R7 are independently selected from the group consisting of C1-C25 alkyl, C6-C10 aryl, C3-C8 cycloalkyl, C2-C22 alkenyl, C3-C8 cycloalkenyl, C7-C32 aralkyl, C7-C32 alkylaryl, C9-C32 aralkenyl, and C9-C32 alkenylaryl; with the provisos that (i) when X is O, Y is O or CH2, and R3 is H, at least one of R2 and R4-­R6 is not OH; (ii) when A is CH2C00H or CH(COOH)2, X and Y cannot be simultaneously O; and (iii) all of R2-R6 are not simultaneously H. The inhibitors can be in the form of a salt also.
    • 公开了丝氨酸/苏氨酸激酶Akt的抑制剂,包含此类抑制剂的药物组合物,以及通过使用这些抑制剂预防或治疗动物的疾病或病症的方法。 Akt抑制剂具有式(I),其中X和Y独立地选自O,CF 2,CH 2和CHF; 其中A独立地选自由P(O)OH,CH2000H和CH(COOH)2组成的组; R2选自OH,OH,C 1 -C 25烷氧基,C 6 -C 10芳氧基,C 3 -C 8环烷氧基,C 3 -C 8环烷基C 1 -C 6烷氧基,C 2 -C 22烯氧基,C 3 -C 8环烯氧基, C7-C32芳烷氧基,C7-C32烷基芳氧基,C9-C32芳烯氧基和C9-C32烯基芳氧基; R3-R6独立地选自H,OH,OH的电子等排体; 且R 1和R 7独立地选自C 1 -C 25烷基,C 6 -C 10芳基,C 3 -C 8环烷基,C 2 -C 22烯基,C 3 -C 8环烯基,C 7 -C 32芳烷基,C 7 -C 32烷基芳基,C 9 -C 32 芳烯基和C 9 -C 32烯基芳基; 条件是(i)当X是O时,Y是O或CH 2,且R 3是H,R 2和R 4 -R 6中的至少一个不是OH; (ii)当A是CH2C00H或CH(COOH)2时,X和Y不能同时为O; 和(iii)R2-R6全部不同时为H.抑制剂也可以是盐的形式。